Maegim한국어

알피바이오

314140KOSDAQSector: Pharma & Biotech
₩5,760▲ 0.52%Market cap ₩49.9BAs of Jul 21, 2026 close · updated once daily
A
Grade A66.8 ptsTop 18% of 2,523 stocks
Financial strength
56.8
Growth momentum
54.9
Price attractiveness
86.8

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

56.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
45.8%
✓ Above median · Top 44.9% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
129.7%
✗ Below median · Top 64% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.7%
✓ Above median · Top 33.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
4.4%
✓ Above median · Top 30.3% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

54.9
How much did revenue grow in a year?
Revenue growth (YoY)
9.9%
✓ Above median · Top 39.5% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-0.5%
✗ Below median · Top 69% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
833.3%
✓ Above median · Top 2.5% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-47.3%
✗ Below median · Top 69.6% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

86.8
Is the price expensive relative to earnings?
P/E (price-to-earnings)
10.7x
✓ Above median · Top 16.1% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.47x
✓ Above median · Top 10.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15